Date: Mar 11, 2014 Author: Greg Barr Source: bizjournals (
click here to go to the source)
Caisson Biotech LLC said Tuesday that it has expanded the scope of its partnership with global pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) to expand the use of the Austin biopharma company's HEPtune drug-delivery technology.
The deal could be worth as much as $167 million in milestone payments, if certain clinical, regulatory and commercial objectives are reached, Caisson said in a statement.
The latest licensing agreement gives Denmark-based Novo Nordisk exclusive rights to commercialize insulin using the HEPTune process, and non-exclusive rights to leverage the HEPtune technology in areas such as human growth hormone therapy, treatments for obesity and for inflammatory diseases.
The HEPtune technology is a patented heparosan-based drug delivery system. Heprosan is a naturally occurring sugar polymer produced by the body that is stable and inert in the bloodstream while being biodegradable.
Greg Barr is the managing editor of Austin Business Journal, responsible for day-to-day digital and print coverage.
